癌分子病態制御学

Molecular Oncology and Therapeutics

癌分子病態制御学 論文業績

癌分子病態制御学 論文業績(2017年7月7日現在)

2017年論文

  1. Ishimoto T, Miyake K, Nandi T, Yashiro M, Onishi N, Huang KK, Lin SJ, Kalpana R, Tay ST, Suzuki Y, Cho BC, Kuroda D, Arima K, Izumi D, Iwatsuki M, Baba Y, Oki E, Watanabe M, Saya H, Hirakawa K, Baba H, Tan P: Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells. Gastroenterology 2017, 153(1):191-204 e116.
  2. Itoh G, Chida S, Yanagihara K, Yashiro M, Aiba N, Tanaka M: Cancer-associated fibroblasts induce cancer cell apoptosis that regulates invasion mode of tumours. Oncogene 2017.
  3. Kasashima H, Yashiro M, Nakamae H, Masuda G, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Nakane T, Hino M, Hirakawa K, Ohira M: Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma. PLoS One 2017, 12(6):e0178635.
  4. Miki Y, Toyokawa T, Kubo N, Tamura T, Sakurai K, Tanaka H, Muguruma K, Yashiro M, Hirakawa K, Ohira M: C-Reactive Protein Indicates Early Stage of Postoperative Infectious Complications in Patients Following Minimally Invasive Esophagectomy. World J Surg 2017, 41(3):796-803.
  5. Sakurai K, Kubo N, Tamura T, Toyokawa T, Amano R, Tanaka H, Muguruma K, Yashiro M, Maeda K, Hirakawa K, Ohira M: Adverse Effects of Low Preoperative Skeletal Muscle Mass in Patients Undergoing Gastrectomy for Gastric Cancer. Ann Surg Oncol 2017.
  6. Tamura T, Kubo N, Yamamoto A, Sakurai K, Toyokawa T, Tanaka H, Muguruma K, Yashiro M, Maeda K, Hirakawa K, Ohira M: Cervical chylous leakage following esophagectomy that was successfully treated by intranodal lipiodol lymphangiography: a case report. BMC Surg 2017, 17(1):20.
  7. Tanaka M, Kuriyama S, Itoh G, Maeda D, Goto A, Tamiya Y, Yanagihara K, Yashiro M, Aiba N: Mesothelial Cells Create a Novel Tissue Niche That Facilitates Gastric Cancer Invasion. Cancer Res 2017, 77(3):684-695.
  8. Tokumoto M, Tanaka H, Tauchi Y, Tamura T, Toyokawa T, Kimura K, Muguruma K, Yashiro M, Maeda K, Hirakawa K, Ohira M: Immunoregulatory Function of Lymphatic Endothelial Cells in Tumor-draining Lymph Nodes of Human Gastric Cancer. Anticancer Res 2017, 37(6):2875-2883.

2016年論文

  1. Hirakawa T, Yashiro M, Doi Y, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Kimura K, Amano R, Hirakawa K: Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia. PLoS One 2016, 11(8):e0159912.
  2. Kasashima H, Yashiro M, Kinoshita H, Fukuoka T, Morisaki T, Masuda G, Sakurai K, Kubo N, Ohira M, Hirakawa K: Lysyl oxidase is associated with the epithelial-mesenchymal transition of gastric cancer cells in hypoxia. Gastric Cancer 2016, 19(2):431-442.
  3. Kasashima H, Yashiro M, Nakamae H, Kitayama K, Masuda G, Kinoshita H, Fukuoka T, Hasegawa T, Nakane T, Hino M, Hirakawa K, Ohira M: CXCL1-Chemokine (C-X-C Motif) Receptor 2 Signaling Stimulates the Recruitment of Bone Marrow-Derived Mesenchymal Cells into Diffuse-Type Gastric Cancer Stroma. Am J Pathol 2016, 186(11):3028-3039.
  4. Masuda GO, Yashiro M, Kitayama K, Miki Y, Kasashima H, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Sakurai K, Toyokawa T, Kubo N, Tanaka H, Muguruma K, Masaichi O, Hirakawa K: Clinicopathological Correlations of Autophagy-related Proteins LC3, Beclin 1 and p62 in Gastric Cancer. Anticancer Res 2016, 36(1):129-136.
  5. Matsuoka T, Yashiro M: Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol 2016, 22(2):776-789.
  6. Miura K, Kimura K, Amano R, Yamazoe S, Ohira G, Murata A, Nishio K, Hasegawa T, Yashiro M, Nakata B, Ohira M, Hirakawa K: Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2. BMC Cancer 2016, 16:268.
  7. Murakami T, Zhang Y, Wang X, Hiroshima Y, Kasashima H, Yashiro M, Hirakawa K, Miwa A, Kiyuna T, Matsuyama R, Tanaka K, Bouvet M, Endo I, Hoffman RM: Orthotopic Implantation of Intact Tumor Tissue Leads to Metastasis of OCUM-2MD3 Human Gastric Cancer in Nude Mice Visualized in Real Time by Intravital Fluorescence Imaging. Anticancer Res 2016, 36(5):2125-2130.
  8. Ohbatake Y, Fushida S, Tsukada T, Kinoshita J, Oyama K, Hayashi H, Miyashita T, Tajima H, Takamura H, Ninomiya I, Yashiro M, Hirakawa K, Ohta T: Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin. Clin Exp Med 2016, 16(4):585-592.
  9. Ohira M, Toyokawa T, Sakurai K, Kubo N, Tanaka H, Muguruma K, Yashiro M, Onoda N, Hirakawa K: Current status in remnant gastric cancer after distal gastrectomy. World J Gastroenterol 2016, 22(8):2424-2433.
  10. Sakurai K, Ohira M, Tamura T, Toyokawa T, Amano R, Kubo N, Tanaka H, Muguruma K, Yashiro M, Maeda K, Hirakawa K: Predictive Potential of Preoperative Nutritional Status in Long-Term Outcome Projections for Patients with Gastric Cancer. Ann Surg Oncol 2016, 23(2):525-533.
  11. Sakurai K, Tamura T, Toyokawa T, Amano R, Kubo N, Tanaka H, Muguruma K, Yashiro M, Maeda K, Ohira M, Hirakawa K: Low Preoperative Prognostic Nutritional Index Predicts Poor Survival Post-gastrectomy in Elderly Patients with Gastric Cancer. Ann Surg Oncol 2016, 23(11):3669-3676.
  12. Takahashi K, Tanaka M, Yashiro M, Matsumoto M, Ohtsuka A, Nakayama KI, Izumi Y, Nagayama K, Miura K, Iwao H, Shiota M: Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells. Cancer Lett 2016, 378(1):8-15.
  13. Tanaka M, Kuriyama S, Itoh G, Kohyama A, Iwabuchi Y, Shibata H, Yashiro M, Aiba N: Identification of anti-cancer chemical compounds using Xenopus embryos. Cancer Sci 2016, 107(6):803-811.
  14. Tauchi Y, Tanaka H, Kumamoto K, Tokumoto M, Sakimura C, Sakurai K, Kimura K, Toyokawa T, Amano R, Kubo N, Muguruma K, Yashiro M, Maeda K, Ohira M, Hirakawa K: Tumor-associated macrophages induce capillary morphogenesis of lymphatic endothelial cells derived from human gastric cancer. Cancer Sci 2016, 107(8):1101-1109.
  15. Toyokawa T, Kubo N, Tamura T, Sakurai K, Amano R, Tanaka H, Muguruma K, Yashiro M, Hirakawa K, Ohira M: The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer 2016, 16:722.
  16. Yashiro M, Matsuoka T: Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer. World J Gastroenterol 2016, 22(8):2415-2423.

2015年論文

  1. Fukuoka T, Yashiro M, Kinoshita H, Morisaki T, Hasegawa T, Hirakawa T, Aomatsu N, Takeda H, Maruyama T, Hirakawa K: Prostaglandin D synthase is a potential novel therapeutic agent for the treatment of gastric carcinomas expressing PPARgamma. Int J Cancer 2015, 137(5):1235-1244.
  2. Hasegawa T, Kubo N, Ohira M, Sakurai K, Toyokawa T, Yamashita Y, Yamazoe S, Kimura K, Nagahara H, Amano R, Shibutani M, Tanaka H, Muguruma K, Ohtani H, Yashiro M, Maeda K, Hirakawa K: Impact of body mass index on surgical outcomes after esophagectomy for patients with esophageal squamous cell carcinoma. J Gastrointest Surg 2015, 19(2):226-233.
  3. Kasashima H, Yashiro M, Nakamae H, Masuda G, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Sakurai K, Toyokawa T, Kubo N, Tanaka H, Muguruma K, Ohira M, Nakane T, Hino M, Hirakawa K: Bone marrow-derived stromal cells are associated with gastric cancer progression. Br J Cancer 2015, 113(3):443-452.
  4. Kinoshita H, Yashiro M, Fukuoka T, Hasegawa T, Morisaki T, Kasashima H, Masuda G, Noda S, Hirakawa K: Diffuse-type gastric cancer cells switch their driver pathways from FGFR2 signaling to SDF1/CXCR4 axis in hypoxic tumor microenvironments. Carcinogenesis 2015, 36(12):1511-1520.
  5. Kurashige J, Mima K, Sawada G, Takahashi Y, Eguchi H, Sugimachi K, Mori M, Yanagihara K, Yashiro M, Hirakawa K, Baba H, Mimori K: Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer invasion and peritoneal dissemination in gastric cancer. Carcinogenesis 2015, 36(1):133-141.
  6. Matsuoka T, Yashiro M: Recent advances in the HER2 targeted therapy of gastric cancer. World J Clin Cases 2015, 3(1):42-51.
  7. Mori Y, Akita K, Yashiro M, Sawada T, Hirakawa K, Murata T, Nakada H: Binding of Galectin-3, a beta-Galactoside-binding Lectin, to MUC1 Protein Enhances Phosphorylation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) and Akt, Promoting Tumor Cell Malignancy. J Biol Chem 2015, 290(43):26125-26140.
  8. Sakurai K, Muguruma K, Nagahara H, Kimura K, Toyokawa T, Amano R, Kubo N, Tanaka H, Ohtani H, Yashiro M, Maeda K, Ohira M, Hirakawa K: The outcome of surgical treatment for elderly patients with gastric carcinoma. J Surg Oncol 2015, 111(7):848-854.
  9. Satoyoshi R, Aiba N, Yanagihara K, Yashiro M, Tanaka M: Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis. Oncogene 2015, 34(24):3176-3187.
  10. Satoyoshi R, Kuriyama S, Aiba N, Yashiro M, Tanaka M: Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts. Oncogene 2015, 34(5):650-660.
  11. Sawada T, Yashiro M, Sentani K, Oue N, Yasui W, Miyazaki K, Kai K, Fushida S, Fujimura T, Ohira M, Kakeji Y, Natsugoe S, Shirabe K, Nomura S, Shimada Y, Tomita N, Hirakawa K, Maehara Y: New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan Society for Gastroenterological Carcinogenesis G-Project committee. Gastric Cancer 2015, 18(1):119-128.
  12. Shinbo T, Fushida S, Tsukada T, Harada S, Kinoshita J, Oyama K, Okamoto K, Ninomiya I, Takamura H, Kitagawa H, Fujimura T, Yashiro M, Hirakawa K, Ohta T: Protein-bound polysaccharide K suppresses tumor fibrosis in gastric cancer by inhibiting the TGF-beta signaling pathway. Oncol Rep 2015, 33(2):553-558.
  13. Tokuhisa M, Ichikawa Y, Kosaka N, Ochiya T, Yashiro M, Hirakawa K, Kosaka T, Makino H, Akiyama H, Kunisaki C, Endo I: Exosomal miRNAs from Peritoneum Lavage Fluid as Potential Prognostic Biomarkers of Peritoneal Metastasis in Gastric Cancer. PLoS One 2015, 10(7):e0130472.
  14. Tokumoto MW, Tanaka H, Tauchi Y, Kasashima H, Kurata K, Yashiro M, Sakurai K, Toyokawa T, Kubo N, Amano R, Kimura K, Muguruma K, Maeda K, Ohira M, Hirakawa K: Identification of tumour-reactive lymphatic endothelial cells capable of inducing progression of gastric cancer. Br J Cancer 2015, 113(7):1046-1054.
  15. Tsuji T, Satoyoshi R, Aiba N, Kubo T, Yanagihara K, Maeda D, Goto A, Ishikawa K, Yashiro M, Tanaka M: Agr2 mediates paracrine effects on stromal fibroblasts that promote invasion by gastric signet-ring carcinoma cells. Cancer Res 2015, 75(2):356-366.
  16. Yamada N, Amano R, Kimura K, Murata A, Yashiro M, Tanaka S, Wakasa K, Hirakawa K: Two-surgeon technique for liver transection using precoagulation by a soft-coagulation system and ultrasonic dissection. Hepatogastroenterology 2015, 62(138):389-392.
  17. Yamaguchi H, Kawazu M, Yasuda T, Soda M, Ueno T, Kojima S, Yashiro M, Yoshino I, Ishikawa Y, Sai E, Mano H: Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer. Cancer Sci 2015, 106(12):1687-1692.
  18. Yashiro M: Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease. Dig Dis Sci 2015, 60(8):2251-2263.
  19. Yashiro M, Matsuoka T: Sentinel node navigation surgery for gastric cancer: Overview and perspective. World J Gastrointest Surg 2015, 7(1):1-9.

2014年論文

  1. Yashiro M. Ulcerative colitis-associated colorectal cancer. World J Gastroenterol. (2014), 20, (16389-97).
  2. Yamaguchi H, Yoshida N, Takanashi M, Ito Y, Fukami K, Yanagihara K, et al. Stromal fibroblasts mediate extracellular matrix remodeling and invasion of scirrhous gastric carcinoma cells. PLoS One. (2014), 9, (e85485).
  3. Amano R, Yamada N, Nakata B, Kimura K, Yashiro M, Ohira M, et al. Prognostic indicator for the resection of liver metastasis of colorectal cancer. Surg Today. (2014), 44, (1287-92).
  4. Aomatsu N, Yashiro M, Kashiwagi S, Kawajiri H, Takashima T, Ohsawa M, et al. Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline. BMC Cancer. (2014), 14, (400).
  5. Asano Y, Kashiwagi S, Shibutani M, Yamazoe S, Noda S, Sakurai K, et al. [Effect of recombinant human soluble thrombomodulin in patients with solid carcinoma with DIC]. Gan To Kagaku Ryoho. (2014), 41, (2503-5).
  6. Fukuoka T, Yashiro M, Kinoshita H, Morisaki T, Hasegawa T, Hirakawa T, et al. Prostaglandin d synthase is a potential novel therapeutic agent for the treatment of gastric carcinomas expressing PPARgamma. Int J Cancer. (2014).
  7. Fukuoka T, Yashiro M, Morisaki T, Kinoshita H, Hasegawa T, Kasashima H, et al. The role of type D prostanoid receptors and PPARgamma in gastric cancer progression. Anticancer Res. (2014), 34, (2771-8).
  8. Hasegawa T, Yashiro M, Nishii T, Matsuoka J, Fuyuhiro Y, Morisaki T, et al. Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-beta signaling. Int J Cancer. (2014), 134, (1785-95).
  9. Kasashima H, Kubo N, Ohira M, Sakurai K, Toyokawa T, Tanaka H, et al. Successful resection of esophageal carcinoma with aberrant right subclavian artery using video-assisted thoracoscopic surgery: report of two cases. Anticancer Res. (2014), 34, (899-904).
  10. Kasashima H, Yashiro M, Kinoshita H, Fukuoka T, Morisaki T, Masuda G, et al. Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts stimulates the progression of gastric cancer. Cancer Lett. (2014), 354, (438-46).
  11. Kiga K, Mimuro H, Suzuki M, Shinozaki-Ushiku A, Kobayashi T, Sanada T, et al. Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. Nat Commun. (2014), 5, (4497).
  12. Kikuchi Y, Kunita A, Iwata C, Komura D, Nishiyama T, Shimazu K, et al. The niche component periostin is produced by cancer-associated fibroblasts, supporting growth of gastric cancer through ERK activation. Am J Pathol. (2014), 184, (859-70).
  13. Kim ST, Jang HL, Lee SJ, Lee J, Choi YL, Kim KM, et al. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol Cancer Ther. (2014), 13, (2527-36).
  14. Kubo N, Ohira M, Yamashita Y, Sakurai K, Lee T, Toyokawa T, et al. Thoracoscopic esophagectomy in the prone position versus in the lateral position for patients with esophageal cancer: a comparison of short-term surgical results. Surg Laparosc Endosc Percutan Tech. (2014), 24, (158-63).
  15. Kubo N, Ohira M, Yamashita Y, Sakurai K, Toyokawa T, Tanaka H, et al. The impact of combined thoracoscopic and laparoscopic surgery on pulmonary complications after radical esophagectomy in patients with resectable esophageal cancer. Anticancer Res. (2014), 34, (2399-404).
  16. Matsuoka T, Yashiro M. Rho/ROCK signaling in motility and metastasis of gastric cancer. World J Gastroenterol. (2014), 20, (13756-66).
  17. Matsuoka T, Yashiro M. The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel). (2014), 6, (1441-63).
  18. Mori Y, Akita K, Tanida S, Ishida A, Toda M, Inoue M, et al. MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-kappaB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells. J Biol Chem. (2014), 289, (35193-204).
  19. Morisaki T, Yashiro M, Kakehashi A, Inagaki A, Kinoshita H, Fukuoka T, et al. Comparative proteomics analysis of gastric cancer stem cells. PLoS One. (2014), 9, (e110736).
  20. Naito Y, Yasuno K, Tagawa H, Sakamoto N, Oue N, Yashiro M, et al. MicroRNA-145 is a potential prognostic factor of scirrhous type gastric cancer. Oncol Rep. (2014), 32, (1720-6).
  21. Nakayama M, Ishibashi T, Ishikawa HO, Sato H, Usui T, Okuda T, et al. A gain-of-function screen to identify genes that reduce lifespan in the adult of Drosophila melanogaster. BMC Genet. (2014), 15, (46).
  22. Sakurai K, Amano R, Yamamoto A, Nishida N, Matsutani S, Hirata K, et al. Portal vein stenting to treat portal vein stenosis in a patient with malignant tumor and gastrointestinal bleeding. Int Surg. (2014), 99, (91-5).
  23. Sakurai K, Muguruma K, Murata A, Toyokawa T, Amano R, Kubo N, et al. Early gastric cancer with suspected brain metastasis arising eight years after curative resection: a case report. BMC Res Notes. (2014), 7, (818).
  24. Sakurai K, Muguruma K, Yamazoe S, Kimura K, Toyokawa T, Amano R, et al. Gastric metastasis from renal cell carcinoma with gastrointestinal bleeding: a case report and review of the literature. Int Surg. (2014), 99, (86-90).
  25. Shiratori H, Yashiro K, Iwai N, Oki S, Minegishi K, Ikawa Y, et al. Self-regulated left-right asymmetric expression of Pitx2c in the developing mouse limb. Dev Biol. (2014), 395, (331-41).

2013年論文

  1. Yashiro M, Nishii T, Matsuzaki T, Hasegawa T, Hirakawa K. A cMet inhibitor increases the chemosensitivity of cancer stem cells to irinotecan in gastric carcinoma. Br J Cancer 109:2619-28. 2013.
  2. Tanida S, Akita K, Ishida A, Mori Y, Inoue M, Ohta M, Yashiro M, Sawada T, Hirakawa K, Nakada H. Binding of the sialic acid binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth. J Biol Chem. 288: 31842-31852, 2013.
  3. Sawada T, Yashiro M, Sentani K, Oue N, Yasui W, Miyazaki K, Kai K, Fujita H, Nakamura K, Maeda K, Shirabe K, Hirakawha K, Maehara Y. New molecular staging with G-factors (VEGF-C and Reg IV) by supplementing TNM classification in colorectal cancers. Oncol Rep. 30: 2609-2616, 2013.
  4. Sato Y, Yashiro M, Takakura N. Heregulin Induces Resistance to Lapatinib-mediated Growth Inhibition of HER2-Amplified Cancer Cells. Cancer Sci. 104: 1618-1625, 2013.
  5. Kubo N, Ohira M, Sakurai K, Toyokawa T, Kimura K, Noda E, Yamada N, Yashiro M, Maeda K, Sawada T, Hirakawa K. SPan-1 is a useful prognostic marker for patients with stage IV gastric cancer who underwent palliative gastrectomy: a retrospective multivariate study. World J Surg. 37:1681-7. 2013.
  6. Nakamoto K, Nagahara H, Maeda K, Noda E, Inoue T, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K. Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer. Oncol Lett. 5:1295-300. 2013.
  7. Matsuoka J, Yashiro M, Doi Y, Fuyuhiro Y, Kato Y, Shinto O, Aomatsu N, Hirakawa T, Hasegawa T, Shimizu K, Shimizu T, Miwa A, Yamada N, Sawada T, Hirakawa K. Hypoxia stimulates the EMT of gastric cancer cells through autocrine TGFbeta signaling. PLoS One. 8:e62310. 2013.
  8. Hirakawa T, Yashiro M, Murata A, Hirata K, Yamada N, Hirakawa K. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with pancreatic cancer. BMC Cancer. 13:392. 2013.
  9. Ohashi M, Oyama T, Putranto EW, Waku T, Nobusada H, Kataoka K, Matsuno K, Yashiro M, Morikawa K, Huh NH, Miyachi H. Design and synthesis of a series of alpha-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility. Bioorg Med Chem. 21:2319-32. 2013.
  10. Tanaka T, Kuramitsu Y, Baron B, Hirakawa K, Yashiro M, Nakamura K. Glyoxalase 1 as a candidate for indicating the metastatic potential of SN12C human renal carcinoma cell clones. Oncol Rep. 2013.
  11. Kubo N, Ohira M, Lee T, Sakurai K, Toyokawa T, Muguruma K, Kimura K, Noda E, Amano R, Ohtani H, Yamashita Y, Yashiro M, Maeda K, Hirakawa K. Successful resection of esophageal cancer with right aortic arch by video-assisted thoracoscopic surgery: a case report. Anticancer Res. 33:1635-40. 2013.
  12. Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Wakasa K, Hirakawa K. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. British J Surg. 100:490-6.2013.
  13. 八代正和、豊川貴弘,櫻井克宣、久保尚士、田中浩明、六車一哉、大平雅一、平川弘聖. スキルス胃癌の病態と治療.消化器外科.へるす出版.36: p1235-1241, 2013.

2012年論文

  1. Doi Y, Yashiro M, Yamada N, Amano R, Noda S, Hirakawa K. VEGF-A/VEGFR-2 Signaling Plays an Important Role for the Motility of Pancreas Cancer Cells. Ann Surg Oncol. 19:2733-43. 2012.
  2. Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M, Wakasa K, Hirakawa K. CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One. 7:e45865. 2012.
  3. Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs. 30:1352-60. 2012.
  4. Yamazaki M, Yamashita Y, Kubo N, Yashiro M, Ohira M, Ako E, Tanaka H, Muguruma K, Sawada T, Hirakawa K. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab. Oncol Rep. 28:49-54. 2012.
  5. Matsuoka J, Yashiro M, Sakurai K, Kubo N, Tanaka H, Muguruma K, Sawada T, Ohira M, Hirakawa K. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res. 174:130-5. 2012.
  6. Yoshii M, Tanaka H, Ohira M, Muguruma K, Iwauchi T, Lee T, Sakurai K, Kubo N, Yashiro M, Sawada T, Hirakawa K. Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach. Br J Cancer. 106:1668-74. 2012.
  7. Harada M, Iwata C, Saito H, Ishii K, Hayashi T, Yashiro M, Hirakawa K, Miyazono K, Kato Y, Kano MR. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo. Int J Nanomedicine. 7:2713-27. 2012.
  8. Ito G, Tanaka H, Ohira M, Yoshii M, Muguruma K, Kubo N, Yashiro M, Yamada N, Maeda K, Sawada T, Hirakawa K. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Exp Ther Med. 3:925-30. 2012.
  9. Kubo N, Ohira M, Yamashita Y, Sakurai K, Tanaka H, Muguruma K, Kimura K, Nagahara H, Noda E, Amano R, Yashiro M, Maeda K, Hirakawa K. Successful resection of esophageal carcinoma associated with double aortic arch: a case report. Anticancer Res. 32:3351-5. 2012.
  10. Nishioka N, Matsuoka T, Yashiro M, Hirakawa K, Olden K, Roberts JD. Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo. Cancer Sci. 103:228-32. 2012.
  11. Rafi M, Cabral H, Kano MR, Mi P, Iwata C, Yashiro M, Hirakawa K, Miyazono K, Nishiyama N, Kataoka K. Polymeric micelles incorporating (1,2-diaminocyclohexane)platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis. J Control Release. 159:189-96. 2012.
  12. Noda E, Maeda K, Inoue T, Fukunaga S, Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K, Yamada N, Yashiro M, Ohira M, Ishikawa T, Hirakawa K. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology. 59:130-3. 2012.
  13. Matsuoka T, Yashiro M, Nishioka N, Hirakawa K, Olden K, Roberts JD. PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma. Br J Cancer. 106:1535-42. 2012.
  14. Katsuno Y, Ehata S, Yashiro M, Yanagihara K, Hirakawa K, Miyazono K. Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumorigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-beta. J Pathol. 228(3):391-404. 2012.
  15. Fuyuhiro Y, Yashiro M, Noda S, Matsuoka J, Hasegawa T, Kato Y, Sawada T, Hirakawa K. Cancer-associated orthotopic myofibroblasts stimulates the motility of gastric carcinoma cells. Cancer Sci. 103:797-805. 2012.
  16. 八代正和,冬廣雄彦、松岡順子、長谷川毅、野田諭,平川弘聖. スキルス胃癌の浸潤・転移-腹膜播種形成の分子機構-. 臨牀消化器内科. 27:1185-89, 2012.
  17. 八代正和、大平雅一、六車一哉、神籐理、平川弘聖. スキルス胃癌の増殖進展機序. 日本臨牀. 70:1812. 2012.
  18. 八代正和, 松岡順子、加藤幸裕、神藤理、松岡翼、平川弘聖. EMTと胃癌. SURGERY FRONTIER. 19. 297-304. 2012.

2011年論文

  1. Yashiro M, Qiu H, Hasegawa T, Zhang X, Matsuzaki T, Hirakawa K. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells. Br J Cancer. 105:1522-32. 2011.
  2. Than SS, Kataoka K, Sakaguchi M, Murata H, Abarzua F, Taketa C, Du G, Yashiro M, Yanagihara K, Nasu Y, Kumon H, Huh NH. Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma. Oncol Rep. 25:989-95. 2011.
  3. Shirai YT, Ehata S, Yashiro M, Yanagihara K, Hirakawa K, Miyazono K. Bone morphogenetic protein-2 and -4 play tumor suppressive roles in human diffuse-type gastric carcinoma. Am J Pathol. 179:2920-30. 2011.
  4. Qiu H, Yashiro M, Zhang X, Miwa A, Hirakawa K. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. Cancer Lett. 307:47-52. 2011.
  5. Noda S, Yashiro M, Toyokawa T, Morimoto J, Shinto O, Muguruma K, Sawada T, Hirakawa K. Borrmann's macroscopic criteria and p-Smad2 expression are useful predictive prognostic markers for cytology-positive gastric cancer patients without overt peritoneal metastasis. Ann Surg Oncol. 18:3718-25. 2011.
  6. Nishioka N, Matsuoka T, Yashiro M, Hirakawa K, Olden K, Roberts JD. Linoleic acid enhances angiogenesis through suppression of angiostatin induced by plasminogen activator inhibitor 1. Br J Cancer. 105:1750-8. 2011.
  7. Matsuoka T, Yashiro M, Kato Y, Shinto O, Kashiwagi S, Hirakawa K. RhoA/ROCK signaling mediates plasticity of scirrhous gastric carcinoma motility. Clin Exp Metastasis. 28:627-36. 2011.
  8. Kato Y, Yashiro M, Fuyuhiro Y, Kashiwagi S, Matsuoka J, Hirakawa T, Noda S, Aomatsu N, Hasegawa T, Matsuzaki T, Sawada T, Ohira M, Hirakawa K. Effects of acute and chronic hypoxia on the radiosensitivity of gastric and esophageal cancer cells. Anticancer Res. 31:3369-75. 2011.
  9. Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Ikeda K, Ogawa Y, Ishikawa T, Hirakawa K. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res. 13:R122. 2011.
  10. Iwauchi T, Tanaka H, Yamazoe S, Yashiro M, Yoshii M, Kubo N, Muguruma K, Sawada T, Ohira M, Hirakawa K. Identification of HLA-A*2402-restricted epitope peptide derived from ERas oncogene expressed in human scirrhous gastric cancer. Cancer Sci. 102:683-9. 2011.
  11. Fuyuhiro Y, Yashiro M, Noda S, Kashiwagi S, Matsuoka J, Doi Y, Kato Y, Hasegawa T, Sawada T, Hirakawa K. Upregulation of cancer-associated myofibroblasts by TGF-beta from scirrhous gastric carcinoma cells. Br J Cancer. 105:996-1001. 2011.
  12. Forster S, Gretschel S, Jons T, Yashiro M, Kemmner W. THBS4, a novel stromal molecule of diffuse-type gastric adenocarcinomas, identified by transcriptome-wide expression profiling. Mod Pathol. 24:1390-403. 2011.
  13. Ehata S, Johansson E, Katayama R, Koike S, Watanabe A, Hoshino Y, Katsuno Y, Komuro A, Koinuma D, Kano MR, Yashiro M, Hirakawa K, Aburatani H, Fujita N, Miyazono K. Transforming growth factor-beta decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene. 30:1693-705. 2011.
  14. 久保尚士、田中浩明、山下好人、六車一哉、八代正和、大平雅一、平川弘聖. 自己血輸血の実際―食道癌手術における自己血輸血の現況―. 外科治療.;104: 235-240, 2011.
  15. 六車一哉、大平雅一、田中浩明、久保尚士、八代正和、山田靖哉、山下好人、澤田鉄二、平川弘聖. 腹腔鏡下胃切除術における視野展開の工夫. 外科治療.;104: 392-396, 2011.
  16. 櫻井克宣、六車一哉、久保尚士、田中浩明、八代正和、澤田鉄二、大平雅一、平川弘聖. 術後の主な合併症とその対策 縫合不全、吻合部通過障害. 外科治療;104: 750-755, 2011.
  17. 野田英児、前田 清、永原 央、天野良亮、久保尚士、田中浩明、六車一哉、山田靖哉、八代正和、大平雅一、石川哲郎、平川弘聖. 腸閉塞. 消化器外科.;34: 1649-1655, 2011.
  18. 野田英児、前田 清、永原 央、木村健二郎、天野良亮、久保尚士、田中浩明、六車一哉、山田靖哉、八代正和、仲田文造、大平雅一、石川哲郎、平川弘聖. 十二指腸・小腸(ダブルバルーン 内視鏡).臨床外科.;66: 1610-1613, 2011.
  19. 柏木伸一郎、前田 清、冬廣雄彦、 永原 央、木村健二郎、天野良亮、野田英児、久保尚士、田中浩明、六車一哉、八代正和、山田靖哉、仲田文造、大平雅一、石川哲郎、平川弘聖. 切除不能進行再発結腸直腸癌に対するXELOX±Bevacizumab療法の治療経験.癌と化学療法.;38: 1936-1938, 2011.
  20. 久保尚士、田中浩明、櫻井克宣、六車一哉、永原 央、木村健二郎、野田英児、天野良亮、山田靖哉、八代正和、前田 清、大平雅一、平川弘聖. 食道癌に対する根治的化学放射線療法後の救済手術(Salvage Esophagectomy)例の検討. 癌と化学療法.;38: 1948-1950, 2011.

2010年論文

  1. Yashiro M, Hirakawa K. Cancer-stromal interactions in scirrhous gastric carcinoma. Cancer Microenviron. 3:127-35. 2010.
  2. Yagi Y, Fushida S, Harada S, Kinoshita J, Makino I, Oyama K, Tajima H, Fujita H, Takamura H, Ninomiya I, Fujimura T, Ohta T, Yashiro M, Hirakawa K. Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res. 29:149. 2010.
  3. Tanaka H, Shinto O, Yashiro M, Yamazoe S, Iwauchi T, Muguruma K, Kubo N, Ohira M, Hirakawa K. Transforming growth factor beta signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep. 24:1637-43. 2010.
  4. Shinto O, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, Matsuzaki T, Noda S, Kubo N, Tanaka H, Doi Y, Ohira M, Muguruma K, Sawada T, Hirakawa K. Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer. 10:652. 2010.
  5. Kuramitsu Y, Baron B, Yoshino S, Zhang X, Tanaka T, Yashiro M, Hirakawa K, Oka M, Nakamura K. Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells. Anticancer Res. 30:4459-65. 2010.
  6. Fuyuhiro Y, Yashiro M, Noda S, Kashiwagi S, Matsuoka J, Doi Y, Kato Y, Kubo N, Ohira M, Hirakawa K. Clinical significance of vimentin-positive gastric cancer cells. Anticancer Res. 30:5239-43. 2010.
  7. Doi Y, Yashiro M, Yamada N, Amano R, Ohira G, Komoto M, Noda S, Kashiwagi S, Kato Y, Fuyuhiro Y, Hirakawa K. Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer. Cancer Sci. 101:1529-35. 2010.
  8. Amano R, Yamada N, Doi Y, Yashiro M, Ohira M, Miwa A, Hirakawa K. Significance of keratinocyte growth factor receptor in the proliferation of biliary tract cancer. Anticancer Res. 30:4115-21. 2010.
  9. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A, Hirakawa K: Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice. Cancer Sci, 101(8):1846-1852, 2010.
  10. Fuyuhiro Y, Yashiro M, Noda S, Kashiwagi S, Matsuoka J, Doi Y, Kato Y, Muguruma K, Sawada T, Hirakawa K. Myofibroblasts are associated with the progression of scirrhous gastric carcinoma. Exp Ther Med. 1:547-551. 2010.
  11. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A, Hirakawa K: Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer, 102(5):844-851, 2010.
  12. Zhao WM, Wang L, Park H, Chhim S, Tanphanich M, Yashiro M, Kim KJ. Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts. Clin Cancer Res.2010.
  13. Zhang X, Yashiro M, Qiu H, Nishii T, Matsuzaki T, Hirakawa K. Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res. 30:915-21. 2010.
  14. Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, Kaizaki R, Miwa A, Hirakawa K. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer. 126:1004-16. 2010.
  15. Yashiro M, Hirakawa K, Boland CR. Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability. BMC Cancer. 10:303. 2010.
  16. Yagi Y, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, Fujita H, Ninomiya I, Fujimura T, Kayahara M, Kinuya S, Yashiro M, Hirakawa K, Ohta T. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol. 66:745-53. 2010.
  17. Noda S, Yashiro M, Nshii T, Hirakawa K. Hypoxia upregulates adhesion ability to peritoneum through a transforming growth factor-beta-dependent mechanism in diffuse-type gastric cancer cells. Eur J Cancer. 46:995-1005. 2010.
  18. Kato Y, Yashiro M, Noda S, Kashiwagi S, Matsuoka J, Fuyuhiro Y, Doi Y, Hirakawa K. Expression of a hypoxia-associated protein, carbonic anhydrase-9, correlates with malignant phenotypes of gastric carcinoma. Digestion. 82:246-51. 2010.
  19. Matsuoka T, Adair JE, Lih FB, Hsi LC, Rubino M, Eling TE, Tomer KB, Yashiro M, Hirakawa K, Olden K, Roberts JD. Elevated dietary linoleic acid increases gastric carcinoma cell invasion and metastasis in mice. Br J Cancer. 103:1182-91. 2010.
  20. Komoto M, Nakata B, Nishii T, Kawajiri H, Shinto O, Amano R, Yamada N, Yashiro M, Hirakawa K. In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. Cancer Sci. 101:468-73. 2010.
  21. Kato Y, Yashiro M, Noda S, Tendo M, Kashiwagi S, Doi Y, Nishii T, Matsuoka J, Fuyuhiro Y, Shinto O, Sawada T, Ohira M, Hirakawa K. Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma. Br J Cancer. 102:898-907. 2010.
  22. Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, Ishikawa T, Wakasa K, Hirakawa K. Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 103:249-55. 2010.
  23. 八代正和. スキルス胃癌. 消化器の臨床 13: 233-239, 2010.
  24. 八代正和、平川弘聖. 胃癌:転移の臨床病理学的特徴. 細胞工学 別冊 がん転移: 32-38, 2010.
  25. 八代正和、六車一哉、平川弘聖.未分化胃癌(sig、por)の特性と自然史. 外科治療103(4): 325-332, 2010.
  26. 六車 一哉, 大平 雅一, 田中 浩明, 久保 尚士, 山田 靖哉, 八代正和, 澤田 鉄二, 仲田 文造, 石川 哲郎, 平川 弘聖. 胃癌に対するリンパ節郭清:消化器外科, 33巻, 1941-1952, 2010.
  27. 天野良亮、山田靖哉、野田英児、久保尚士、田中浩明、六車一哉、高島 勉、八代正和、前田 清、小野田尚佳、澤田鉄二、仲田文造、大平雅一、石川哲郎、平川弘聖. 進行肝細胞癌に対するソラフェニブの治療成績. 癌と化学療法;37:2676-2678, 2010.
  28. 田中 浩明, 六車 一哉, 久保 尚士, 天野 良亮, 野田 英児, 山田 靖哉, 八代正和, 前田 清, 澤田 鉄二, 大平 雅一, 石川 哲郎, 平川 弘聖. Stage II/III胃癌に対するPSK術後補助療法のResponderの予測:癌と化学療法 37巻 2258-2260, 2010.
  29. 久保 尚士(大阪市立大学 大学院医学研究科腫瘍外科), 森本 純也, 櫻井 克宣, 田中 浩明, 六車 一哉, 天野 良亮, 野田 英児, 永原 央, 高島 勉, 八代正和, 山田 靖哉, 小野田 尚佳, 前田 清, 澤田 鉄二, 仲田 文造, 大平 雅一, 石川 哲郎, 平川 弘聖. 局所進行再発食道癌に対するDocetaxel併用化学放射線療法:癌と化学療法 37巻, 2261-2263, 2010.

2009年論文

  1. Yashiro M, Yasuda K, Nishii T, Kaizaki R, Sawada T, Ohira M, Hirakawa K. Epigenetic regulation of the embryonic oncogene ERas in gastric cancer cells. Int J Oncol. 35:997-1003 .2009.
  2. Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, Kaizaki R, Ohira M, Miwa A, Hirakawa K. Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer. 101:1100-6. 2009.
  3. Yashiro M, Inoue T, Nishioka N, Matsuoka T, Boland CR, Hirakawa K. Allelic Imbalance at p53 and Microsatellite Instability Are Predictive Markers for Resistance to Chemotherapy in Gastric Carcinoma. Ann Surg Oncol. 16(10):2926-35, 2009.
  4. Wada K, Tanaka H, Maeda K, Inoue T, Noda E, Amano R, Kubo N, Muguruma K, Yamada N, Yashiro M, Sawada T, Nakata B, Ohira M, Hirakawa K. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep. 22:1021-5.2009.
  5. Toyokawa T, Yashiro M, Hirakawa K. Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep. 21:875-80.2009.
  6. Semba S, Kodama Y, Ohnuma K, Mizuuchi E, Masuda R, Yashiro M, Hirakawa K, Yokozaki H. Direct cancer-stromal interaction increases fibroblast proliferation and enhances invasive properties of scirrhous-type gastric carcinoma cells. Br J Cancer. 101:1365-73.2009.
  7. Qiu H, Yashiro M, Shinto O, Matsuzaki T, Hirakawa K. DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells. Cancer Sci. 100:181-8.2009.
  8. Nishii T, Yashiro M, Shinto O, Sawada T, Ohira M, Hirakawa K. Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci. 100:1397-402.2009.
  9. Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M, Hirakawa K. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci. 100:2402-10. 2009.
  10. Komuro A, Yashiro M, Iwata C, Morishita Y, Johansson E, Matsumoto Y, Watanabe A, Aburatani H, Miyoshi H, Kiyono K, Shirai YT, Suzuki HI, Hirakawa K, Kano MR, Miyazono K. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling. J Natl Cancer Inst. 101:592-604.2009.
  11. Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, Wakasa K, Hirakawa K. HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci. 100:1243-7.2009.
  12. Kinoshita J, Fushida S, Harada S, Yagi Y, Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M, Hirakawa K, Ohta T. Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int J Oncol. 34:1573-82.2009.
  13. Kaizaki R, Yashiro M, Shinto O, Yasuda K, Matsuzaki T, Sawada T, Hirakawa K. Expression of ERas oncogene in gastric carcinoma. Anticancer Res. 29:2189-93.2009.
  14. 八代正和,川尻成美,神藤理,濱島好男,梶本哲也,野出学,平川弘聖. スキルス胃癌への新しいアプローチ スキルス胃癌の病態に基づいた分子標的治療:TGFβレセプター阻害剤による腹膜転移抑制. 癌の臨床.;55(1):81(81)-90(90), 2009.
  15. 八代正和,豊川貴弘,鰐渕英機,小野田尚佳,羽室雅夫,渡辺俊雄,斯波将次,六車一哉,富永和作,山下好人,澤田鉄二,大平雅一,平川弘聖,上田真喜子. 臨床病理カンファレンス9 残胃癌. 綜合臨床. ;58(2):370-377, 2009.
  16. 八代正和,神藤理,豊川貴弘,川尻成美,中村和憲,平川弘聖. 消化器疾患の分子医学―基礎医学から臨床へ 消化器疾患と分子標的薬. 臨牀消化器内科. ;24(2):193-200, 2009.
  17. 八代正和. 分子標的治療薬の研究が進み、スキルス胃がん治療に光が見えてきた. 監修・八代正和.がんサポート 特集 胃がん・食道がん.;69:34-37, 2009.
  18. 八代正和,達脇大,大澤政彦,伊倉義弘,渡辺憲治,押谷伸英,前田清,松本誉之,荒川哲男,平川弘聖,上田真樹子. 臨床カンファレンス17 炎症性腸疾患―潰瘍性大腸炎を中心として. 綜合臨牀.;58(10):2178-2187, 2009.
  19. 野田英児,前田清,井上透,高島勉,小野田尚佳,山田靖哉,八代正和,澤田鉄二,仲田文造,大平雅一,石川哲郎,平川弘聖. 癌の告知. 消化器外科.;32(5):973-975, 2009.
  20. 前田清,野田英児,井上透,押谷伸英,渡辺憲治,山上博一,鎌田紀子,十河光栄,八代正和,山田靖哉,西口幸雄,池原照幸,平川弘聖. 潰瘍性大腸炎に対する腹腔鏡手術-緊急度別にみた術式選択-. 日本大腸肛門病学会雑誌.;62(7):453-460, 2009.
  21. 豊川貴弘,澤田鉄二,久保尚士,田中浩明,六車一哉,八代正和,大平雅一,平川弘聖. 特集 できる!縫合・吻合 Ⅲ.部位(術式)別の縫合・吻合法 3.胃 十二指腸切開部の手縫いによる縫合閉鎖. 臨床外科.;64(11):172-173, 2009.
  22. 田中浩明,山添定明,岩内武彦,久保尚士,六車一哉,八代正和,山田靖哉,澤田鉄二,大平雅一,平川弘聖. PSKとTGF-β阻害剤の併用による癌宿主の免疫応答増強効果. 癌と化学療法.;36(12):1969-1971, 2009.
  23. 久保尚士,森本純也,田中浩明,大平雅一,野田英児,天野良亮,井上透,山田靖哉,八代正和,前田清,山下好人,六車一哉,澤田鉄二,平川弘聖. 局所進行食道癌に対する5-FU/Nedaplantin(CDGP)による化学放射線療法. 癌と化学療法.;36:1997-1999, 2009.
  24. 天野良亮,山田靖哉,野田英児,久保尚士,田中浩明,六車一哉,井上透,八代正和,前田清,小野田尚佳,澤田鉄二,仲田文造,大平雅一,石川哲郎,平川弘聖. 大腸癌肝転移症例に対するFOLFOXを中心とした術前化学療法の成績. 癌と化学療法.;36:2003-2005, 2009.
  25. 前田 清, 野田 英児, 井上 透, 押谷 伸英, 渡辺 憲治, 山上 博一, 鎌田 紀子, 十河 光栄, 八代正和, 山田 靖哉, 西口 幸雄, 池原 照幸, 平川 弘聖. 潰瘍性大腸炎に対する腹腔鏡手術 緊急度別にみた術式選択:日本大腸肛門病学会雑誌62巻453-460, 2009.
  26. 野田諭,久保尚士,田中浩明,六車一哉,八代正和,山田靖哉,前田清,澤田鉄二,大平雅一,石川哲郎,平川弘聖. 集学的治療が奏効し長期間CRを維持している腹部大動脈周囲リンパ節転移を伴った進行食道癌の1例. 癌と化学療法.;36:2451-2453, 2009.

2008年論文

  1. Noda E, Ishikawa T, Maeda K, Inoue T, Amano R, Kubo N, Tanaka H, Muguruma K, Yamashita Y, Yashiro M, Yamada N, Onoda N, Sawada T, Nishiguchi Y, Ohira M, Hirakawa K. Laparoscopic resection of periadrenal paraganglioma: a report of 2 cases. Surg Laparosc Endosc Percutan Tech. 18:310-4. 2008.
  2. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68:2340-8. 2008.
  3. Kawajiri H, Yashiro M, Shinto O, Nakamura K, Tendo M, Takemura S, Node M, Hamashima Y, Kajimoto T, Sawada T, Ohira M, Hirakawa K. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res. 14:2850-60. 2008.
  4. Fujiwara I, Yashiro M, Kubo N, Maeda K, Hirakawa K. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis Colon Rectum. 51:1387-94. 2008.
  5. Ako E, Ohira M, Yamashita Y, Kubo N, Muguruma K, Yashiro M, Sawada T, Nakata B, Kato Y, Hirakawa K. Efficacy of S-1 for gastric cancer patients with positive peritoneal lavage cytology. Hepatogastroenterology. 55:1939-42. 2008.
  6. 八代正和, 鰐渕英機, 町田浩久, 前田清, 高田佳江, 松田常美, 仲田文造, 田代敬彦, 中村肇, 天道正成, 西原承浩, 西野裕二, 平川弘聖, 上田真喜子. 臨床病理カンファレンス 大腸癌. 綜合臨床(0371-1900)57巻9号 Page2396-2404, 2008.
  7. 八代正和,石川哲郎、平川弘聖.胃癌のすべて:スキルス胃癌. 消化器外科31巻5号 866-872、2008.
  8. 八代正和 , 石川哲郎, 平川弘聖. スキルス胃癌の進展機序と線維芽細胞の増殖. 日本臨床66巻増刊5 胃癌, 2008.
  9. 八代正和, 川尻成美, 神藤理, 濱島好男, 梶本哲也, 野出学, 平川弘聖. TGFβ受容体阻害剤を用いた胃癌分子標的治療. 日本臨床 66巻475-479, 2008.
  10. 平川弘聖、八代正和. スキルス (linitis plastica 型) 胃癌における癌細胞の特性、治療に向けた将来展望. 胃と腸 43(5): 833-844, 2008.
  11. 豊川 貴弘(大阪市立大学 大学院腫瘍外科), 八代正和, 大平 雅一, 石川 哲郎, 平川 弘聖.予後予測因子の研究 K-samと胃癌の予後:日本臨床66 496-499, 2008.
  12. 天野良亮, 山田靖哉, 八代正和, 澤田鉄二, 大平雅一, 平川弘聖. 腹壁・鼠径部領域 腹壁. 手術62巻6号 Page705-709, 2008.
  13. 田中浩明, 八代正和, 西岡伸明, 豊川貴弘, 久保尚士, 六車一哉, 山下好人, 澤田鉄二, 大平雅一, 平川弘聖. 予後予測因子の研究 Desmoglein-2分子とスキルス胃癌の予後. 日本臨床66巻増刊5 胃癌 509-513, 2008.
  14. 八木康道, 伏田幸夫, 藤田秀人, 木南伸一, 二宮致, 藤村隆, 萱原正都, 太田哲生, 八代正和, 平川弘聖. 胃癌腹膜播種モデルにおける薬物動態を考慮した抗VEGF療法. 癌と化学療法35巻12号 2005-2008, 2008.

2007年までの論文

  1. Yasuda K, Yashiro M, Sawada T, Ohira M, Hirakawa K. ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells. Anticancer Res. 27:4071-5. 2007.
  2. Yashiro M, Nakazawa K, Tendo M, Kosaka K, Shinto O, Hirakawa K. Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial-mesenchymal interactions of growth in scirrhous gastric carcinoma. Int J Cancer. 120:686-93. 2007.
  3. Sakurai K, Yamada N, Yashiro M, Matsuzaki T, Komatsu M, Ohira M, Miwa A, Hirakawa K. A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver. Eur J Cancer. 43:2612-20. 2007.
  4. Kosaka K, Yashiro M, Sakate Y, Hirakawa K. A synergistic antitumor effect of interleukin-2 addition with CD80 immunogene therapy for peritoneal metastasis of gastric carcinoma. Dig Dis Sci. 52:1946-53. 2007.
  5. Katsuragi K, Yashiro M, Sawada T, Osaka H, Ohira M, Hirakawa K. Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. Br J Cancer. 97:550-6. 2007.
  6. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A. 104:3460-5. 2007.
  7. Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi M, Miyazono K. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res. 67:10181-9. 2007.
  8. Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep. 16:563-8. 2006.
  9. Yashiro M, Nishioka N, Hirakawa K. Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer. 42:2397-403. 2006.
  10. Zhang X, Yashiro M, Ohira M, Ren J, Hirakawa K. Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Sci. 97:938-44. 2006.
  11. Tendo M, Yashiro M, Nakazawa K, Yamada N, Sawada T, Ohira M, Hirakawa K. A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett. 244:247-51. 2006.
  12. Sawada T, Kimura K, Nishihara T, Onoda N, Teraoka H, Yamashita Y, Yamada N, Yashiro M, Ohira M, Hirakawa K. TGF-beta1 down-regulates ICAM-1 expression and enhances liver metastasis of pancreatic cancer. Adv Med Sci. 51:60-5. 2006.
  13. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology. 131:1530-41. 2006.
  14. Mino A, Onoda N, Yashiro M, Aya M, Fujiwara I, Kubo N, Sawada T, Ohira M, Kato Y, Hirakawa K. Frequent p16 CpG island hypermethylation in primary remnant gastric cancer suggesting an independent carcinogenic pathway. Oncol Rep. 15:615-20. 2006.
  15. Hosono S, Ohira M, Maeda K, Muguruma K, Nishihara T, Inoue T, Yashiro M, Hirakawa K. Synchronous adenocarcinomas of the ileum and transverse colon detected by capsule endoscopy: report of a case. Surg Today. 36:663-5. 2006.
  16. NamikiY, Namiki T, Yoshida H, Date M, Yashiro M, Matsumoto K, Nakamura T, Yanagihara K, Tada N, Satoi J, Fujise K. Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressatrade mark) for disseminated peritoneal scirrhous gastric cancer. Int J Cancer. 118: 1545-1555, 2006.
  17. Aya M, Yashiro M, Nishioka N, Onoda N, Hirakawa K. Carcinogenesis in the remnant stomach following distal gastrectomy with billroth II reconstruction is associated with high-level microsatellite instability. Anticancer Res. 26:1403-11. 2006.
  18. Yashiro M, Sunami T, Hirakawa K. CD54 expression is predictive for lymphatic spread in human gastric carcinoma. Dig Dis Sci. 50:2224-30. 2005.
  19. Yashiro M, Nishioka N, Hirakawa K. K-ras mutation influences macroscopic features of gastric carcinoma. J Surg Res. 124:74-8. 2005.
  20. Yashiro M, Laghi L, Saito K, Carethers JM, Slezak P, Rubio C, Hirakawa K, Boland CR. Serrated adenomas have a pattern of genetic alterations that distinguishes them from other colorectal polyps. Cancer Epidemiol Biomarkers Prev. 14:2253-6. 2005.
  21. Yashiro M, Ikeda K, Tendo M, Ishikawa T, Hirakawa K. Effect of organ-specific fibroblasts on proliferation and differentiation of breast cancer cells. Breast Cancer Res Treat. 90:307-13. 2005.
  22. Yamada S, Yashiro M, Maeda K, Nishiguchi Y, Hirakawa K. A novel high-specificity approach for colorectal neoplasia: Detection of K-ras2 oncogene mutation in normal mucosa. Int J Cancer. 113:1015-21. 2005.
  23. Tendo M, Yashiro M, Nakazawa K, Yamada N, Hirakawa K. Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells. Cancer Sci. 96:451-5. 2005.
  24. Tachimori A, Yamada N, Sakate Y, Yashiro M, Maeda K, Ohira M, Nishino H, Hirakawa K. Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma. Eur J Cancer. 41:1802-10. 2005.
  25. Matsumura Y, Yashiro M, Ohira M, Tabuchi H, Hirakawa K. 5-Fluorouracil up-regulates interferon pathway gene expression in esophageal cancer cells. Anticancer Res. 25:3271-8. 2005.
  26. Kubo N, Yashiro M, Ohira M, Hori T, Fujiwara I, Hirakawa K. Frequent microsatellite instability in primary esophageal carcinoma associated with extraesophageal primary carcinoma. Int J Cancer. 114:166-73. 2005.
  27. Inoue M, Sawada T, Uchima Y, Kimura K, Nishihara T, Tanaka H, Yashiro M, Yamada N, Ohira M, Hirakawa K. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis. Oncol Rep. 14:1445-51. 2005.
  28. Yashiro M, Kobayashi H, Kubo N, Nishiguchi Y, Wakasa K, Hirakawa K. Cronkhite-Canada syndrome containing colon cancer and serrated adenoma lesions. Digestion. 69:57-62. 2004.
  29. Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, Hirakawa K. ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res. 10:4885-92. 2004.
  30. Takemura S, Yashiro M, Sunami T, Tendo M, Hirakawa K. Novel models for human scirrhous gastric carcinoma in vivo. Cancer Sci. 95:893-900. 2004.
  31. Sawai M, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K. Growth-inhibitory effects of the ketone body, monoacetoacetin, on human gastric cancer cells with succinyl-CoA: 3-oxoacid CoA-transferase (SCOT) deficiency. Anticancer Res. 24:2213-7. 2004.
  32. Sakate Y, Yashiro M, Tanaka H, Sunami T, Kosaka K, Hirakawa K. Usefulness of inhibiting the lymph node metastasis in human gastric carcinoma by B7-1 gene transfection. J Surg Res. 122:89-95. 2004.
  33. Sakate Y, Yashiro M, Tanaka H, Kosaka K, Ohira M, Hirakawa K. Suppression of peritoneal metastasis in human gastric carcinoma by enhanced immunogenicity of B7-1 transfection. Oncol Rep. 12:53-7. 2004.
  34. Osaka H, Yashiro M, Sawada T, Katsuragi K, Hirakawa K. Is a lymph node detected by the dye-guided method a true sentinel node in gastric cancer? Clin Cancer Res. 10:6912-8.2004.
  35. Namiki Y, Namiki T, Date M, Yanagihara K, Yashiro M, Takahashi H. Enhanced photodynamic antitumor effect on gastric cancer by a novel photosensitive stealth liposome. Pharmacol Res. 50:65-76. 2004.
  36. Osaka H, Yashiro M, Nishino H, Nakata B, Ohira M, Hirakawa K. A case of osteoclast-type giant cell tumor of the pancreas with high-frequency microsatellite instability. Pancreas. 29:239-41. 2004.
  37. Koyama T, Yashiro M, Matsuoka T, Sunami T, Ohira M, Hirakawa K. Establishment of a new scirrhous gastric carcinoma cell line with microsatellite instability. Oncol Rep. 12:317-21. 2004.
  38. Kosaka K, Yashiro M, Sakate Y, Tanaka H, Sunami T, Ohira M, Hirakawa K. CD80 gene therapy for lymph node involvement by gastric carcinoma. Int J Oncol. 25:1319-25. 2004.
  39. Yashiro M, Murahashi K, Matsuoka T, Nakazawa K, Tanaka H, Osaka H, Koyama T, Ohira M, Chung KH. Tranilast (N-3,4-dimethoxycinamoyl anthranilic acid): a novel inhibitor of invasion-stimulating interaction between gastric cancer cells and orthotopic fibroblasts. Anticancer Res. 23:3899-904. 2003.
  40. Watanabe A, Hippo Y, Taniguchi H, Iwanari H, Yashiro M, Hirakawa K, Kodama T, Aburatani H. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res. 63:8629-33. 2003.
  41. Nakazawa K, Yashiro M, Hirakawa K. Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res. 63:8848-52. 2003.
  42. Nakata B, Wang YQ, Yashiro M, Ohira M, Ishikawa T, Nishino H, Seki S, Hirakawa K. Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients. Oncol Rep. 10:997-1000. 2003.
  43. Maeda K, Yashiro M, Nishihara T, Nishiguchi Y, Sawai M, Uchima K, Onoda N, Ohira M, Ishikawa T, Hirakawa K. Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum. Surg Today.33:736-9. 2003.
  44. Tanaka H, Yashiro M, Sunami T, Ohira M, Hirakawa YSCK. Lipid-mediated gene transfection of intercellular adhesion molecule-1 suppresses the peritoneal metastasis of gastric carcinoma. Int J Mol Med. 10:613-7. 2002.
  45. Shinto O, Yashiro M, Yamada N, Matsuoka T, Ohira M, Ishikawa T, Nishino H, Hirakawa K. Primary leiomyosarcoma of the breast: report of a case. Surg Today. 32:716-9. 2002.
  46. Nakata B, Yashiro M, Nishioka N, Aya M, Yamada S, Takenaka C, Ohira M, Ishikawa T, Nishino H, Wakasa K, Seki S, Hirakawa K. Very low incidence of microsatellite instability in intraductal papillary-mucinous neoplasm of the pancreas. Int J Cancer. 102:655-9. 2002.
  47. Nakata B, Yashiro M, Nishioka N, Aya M, Yamada S, Takenaka C, Ohira M, Ishikawa T, Nishino H, Wakasa K, Hirakawa K. Genetic alterations in adenoma-carcinoma sequencing of intraductal papillary-mucinous neoplasm of the pancreas. Int J Oncol. 21:1067-72. 2002.
  48. Nakata B, Wang YQ, Yashiro M, Nishioka N, Tanaka H, Ohira M, Ishikawa T, Nishino H, Hirakawa K. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res. 8:2536-40. 2002.
  49. Maeda K, Kang SM, Sawada T, Nishiguchi Y, Yashiro M, Ogawa Y, Ohira M, Ishikawa T, Hirakawa YSCK. Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol Rep. 9:511-4. 2002.
  50. Yukimoto K, Nakata B, Muguruma K, Yashiro M, Ohira M, Ishikawa T, Hino M, Hirakawa K. Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastric cancer cells with or without p53 mutation. Int J Oncol. 19:373-8. 2001.
  51. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, Rubio C, Koizumi K, Hirakawa K, Boland CR. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res. 61:2676-83. 2001.
  52. Teraoka H, Sawada T, Nishihara T, Yashiro M, Ohira M, Ishikawa T, Nishino H, Hirakawa K. Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer. 85:612-7. 2001.
  53. Nishioka N, Yashiro M, Inoue T, Matsuoka T, Ohira M, Chung KH. A candidate tumor suppressor locus for scirrhous gastric cancer at chromosome 18q 12.2. Int J Oncol. 18:317-22. 2001.
  54. Murahashi K, Yashiro M, Takenaka C, Matsuoka T, Ohira M, Chung KH. Establishment of a new scirrhous gastric cancer cell line with loss of heterozygosity at E-cadherin locus. Int J Oncol. 19:1029-33. 2001.
  55. Maeda K, Nishiguchi Y, Kang SM, Yashiro M, Onoda N, Sawada T, Ishikawa T, Hirakawa K. Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep. 8:763-6. 2001.
  56. Ikeda K, Yashiro M, Sawada T, Hato F, Hasuma T, Ishikawa T, Hirakawa YK. M(R) 77 KDA factor derived from fibroblasts stimulates the invasion ability of breast-cancer cells. Int J Cancer. 92:181-6. 2001.
  57. Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, Kodama T, Aburatani H. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 61:889-95. 2001.
  58. Matsuoka T, Yashiro M, Sawada T, Ishikawa T, Ohira M, Hirakawa K, Chung YS. Effect of a matrix metalloproteinase inhibitor on a lymph node metastatic model of gastric cancer cells passaged by orthotopic implantation. J Exp Clin Cancer Res.20:213-8. 2001.
  59. Sunami T, Yashiro M, Chung KH. ICAM-1 (intercellular adhesion molecule-1) gene transfection inhibits lymph node metastasis by human gastric cancer cells. Jpn J Cancer Res. 91:925-33. 2000.
  60. Ohtani H, Yashiro M, Onoda N, Nishioka N, Kato Y, Yamamoto S, Fukushima S, Hirakawa-Ys Chung K. Synchronous multiple primary gastrointestinal cancer exhibits frequent microsatellite instability. Int J Cancer. 86:678-83. 2000.
  61. Nakata B, Hori T, Sunami T, Ogawa Y, Yashiro M, Maeda K, Sawada T, Kato Y, Ishikawa T, Hirakawa K. Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res. 6:1175-9. 2000.
  62. Muguruma K, Nakata B, Yanagawa K, Nitta A, Yashiro M, Onoda N, Hirakawa K. Caspase-1 activity as a possible predictor of apoptosis induced by cisplatin in gastric cancer cells. Int J Mol Med. 6:553-7. 2000.
  63. Matsuoka T, Yashiro M, Sawada T, Ishikawa T, Ohira M, Chung KH. Inhibition of invasion and lymph node metastasis of gastrointestinal cancer cells by R-94138, a matrix metalloproteinase inhibitor. Anticancer Res. 20:4331-8. 2000.
  64. Matsuoka T, Yashiro M, Nishimura S, Inoue T, Fujihara T, Sawada T, Kato Y, Seki S, Hirakawa-Ys Chung K. Increased expression of alpha2beta1-integrin in the peritoneal dissemination of human gastric carcinoma. Int J Mol Med. 5:21-5. 2000.
  65. Maeda K, Nishiguchi Y, Yashiro M, Yamada S, Onoda N, Sawada T, Kang SM, Hirakawa K. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med. 5:373-8. 2000.
  66. Koyama T, Yashiro M, Inoue T, Nishimura S, Hirakawa YSCK. TGF-beta1 secreted by gastric fibroblasts up-regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol. 16:355-62. 2000.
  67. Inoue T, Yashiro M, Nishimura S, Maeda K, Sawada T, Ogawa Y, Sowa M, Chung KH. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med. 4:73-7. 1999.
  68. Fujihara T, Yashiro M, Inoue T, Sawada T, Kato Y, Ohira M, Nishiguchi Y, Ishikawa T, Sowa M, Chung KH. Decrease in ICAM-1 expression on gastric cancer cells is correlated with lymph node metastasis. Gastric Cancer. 2:221-25. 1999.
  69. Nishimura S, Hirakawa-Chung KY, Yashiro M, Inoue T, Matsuoka T, Fujihara T, Murahashi K, Sawada T, Nakata B, Jikihara I, Takagi H, Sowa M. TGF-beta1 produced by gastric cancer cells affects mesothelial cell morphology in peritoneal dissemination. Int J Oncol. 12:847-51. 1998.
  70. Murahashi K, Yashiro M, Inoue T, Nishimura S, Matsuoka T, Sawada T, Sowa M, Hirakawa-Ys Chung K. Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol. 13:1235-40. 1998.
  71. Matsuoka T, Hirakawa K, Chung YS, Yashiro M, Nishimura S, Sawada T, Saiki I, Sowa M. Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis. 16:381-8. 1998.
  72. Fujihara T, Sawada T, Hirakawa K, Chung YS, Yashiro M, Inoue T, Sowa M. Establishment of lymph node metastatic model for human gastric cancer in nude mice and analysis of factors associated with metastasis. Clin Exp Metastasis. 16:389-98. 1998.
  73. Yashiro M, Chung YS, Sowa M. Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. Anticancer Res. 17:895-900. 1997.
  74. Nitta A, Chung YS, Nakata B, Yashiro M, Onoda N, Maeda K, Sawada T, Sowa M. Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP. Cancer Chemother Pharmacol. 40:94-7. 1997.
  75. Inoue T, Chung YS, Yashiro M, Nishimura S, Hasuma T, Otani S, Sowa M. Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res. 88:152-9. 1997.
  76. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination. Cancer. 77:1668-75. 1996.
  77. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis. 14:43-54. 1996.
  78. Yashiro M, Chung YS, Kubo T, Hato F, Sowa M. Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br J Cancer. 74:1096-103. 1996.
  79. Yashiro M, Chung YS, Inoue T, Nishimura S, Matsuoka T, Fujihara T, Sowa M. Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination. Int J Cancer. 67:289-93. 1996.
  80. Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M. CD44H plays an important role in peritoneal dissemination of scirrhous gastric cancer cells. Jpn J Cancer Res. 87:1235-44. 1996.
  81. Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M. Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer. 74:1406-12. 1996.
  82. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer. 72:1200-10. 1995.
  83. Yashiro M, Chung YS, Sowa M. Role of orthotopic fibroblasts in the development of scirrhous gastric carcinoma. Jpn J Cancer Res. 85:883-6. 1994.
  84. 八代正和, 中村和憲, 豊川貴弘, 川尻成美, 神藤理, 井上透, 澤田鉄二, 大平雅一, 三輪篤史, 平川弘聖。FGF-R2/K-samIIを分子標的としたスキルス胃癌の新規治療法。消化器科, 44巻, 447-454,2007.
  85. 井上透, 前田清, 野田英児, 八代正和, 平川弘聖. 切除不能悪性大腸狭窄に対するメタリックステント留置術. 消化器内視鏡19巻9号 1323-1328, 2007.
  86. 竹村哲, 八代正和, 澤田鉄二, 大平雅一, 平川弘聖。.54.ベッドサイドで必要な外科基本手技と管理指針 胃ゾンデ・イレウス管の挿入と管理。.外科治療96巻3号 281-288、.2007.
  87. 葛城圭, 八代正和, 澤田鉄二, 平川弘聖。.55.同時性多発胃癌。.外科治療96巻増刊 450-454。.2007.
  88. 前田清, 井上透, 野田英児, 西原承浩, 八代正和, 福永真也, 平川弘聖。.56.QOLからみた切除不能大腸悪性狭窄に対するステント留置術の有用性。.日本腹部救急医学会雑誌27巻6号 839-843.2007.
  89. 藤原一郎, 八代正和, 山下好人, 澤田鉄二, 平川弘聖. 自動縫合器(リニアステイプラーを中心に)。.手術61巻8号 1079-1087.2007.
  90. 八代正和、平川弘聖。腹膜播種性転移の病態メカニズムと分子標的治療。臨床外科 61: 733-740, 2006.
  91. 八代正和、平川弘聖. スキルス胃癌. 最新の動向と今後の展望. 医学のあゆみ 別冊消化器疾患 ver 3: 550-553, 2006.
  92. 八代正和、井上 透、澤田鉄二、大平雅一、 平川弘聖. スキルス胃癌における線維化は癌の進展にどのようにかかわるのか? 分子消化器病 3(3): 245-250, 2006.
  93. 井上透, 前田清, 八代正和, 西原承浩, 西口幸雄, 平川弘聖. 潰瘍性大腸炎緊急手術例に対する腹腔鏡補助下小開腹手術. 日本腹部救急医学会雑誌26巻1号 43-46, 2006.
  94. 前田 清、井上 透、西原承浩、八代正和、野田英児、福永真也、岡崎博俊、杉森聖司、山下好人、大平雅一、平川弘聖: 消化管狭窄に対するステント留置. 臨床外科 61: 1159-1164, 2006.
  95. 前田 清、井上 透、西原承浩、八代正和、野田英児、西口幸雄,平川弘聖.49.悪性大腸癌における金属ステント留置の有用性.日本腹部救急医学会雑誌25(3);513-515. 2005.
  96. 内間恭武,前田 清,堀 武治,大澤尚志,堀江秀樹,井上 透,西原承浩,八代正和,澤田鉄二,平川弘聖.50.胃癌腹膜播種性転移による大腸狭窄に対するステント治療の経験.日本消化器内視鏡学会雑誌 47 (8) 1548-1553,.2005.
  97. 小坂錦司、八代正和、坂手洋二、田中浩明、須浪 毅、平川弘聖.46.外科領域における分子標的治療胃癌リンパ節転移機序解明と遺伝子治療.癌の治療 50(10);815-819.2004.
  98. 前田 清、八代正和、西原承浩、井上 透、西口幸雄、平川弘聖.47.潰瘍性大腸炎に対する腹腔鏡併用小開腹下大腸全摘術.手術 58(11);1879-1882.2004.
  99. 前田清, 西口幸雄, 八代正和, 西原承浩, 松本誉之, 平川弘聖.48.Crohn病合併痔瘻に対するクシャラ・スートラを用いたminimal seton手術.手術, 58(1): 103-106,.2004.
  100. 八代正和、前田 清、井上 透、平川弘聖.45.悪性大腸狭窄に対する内視鏡下ステント留置術.手術, 57(11);1389-1392,.2003.
  101. 八代正和、平川弘聖. 間質細胞との相互作用からみたスキルス胃癌の分子標的治療. Surgery Frontier 9(4): 381-386, 2002.
  102. 平川弘聖、澤田鉄二、山下好人、八代正和.40.難治性癌に対する戦略~スキルス胃癌.Practical Oncology 15(4);12-14.2002.
  103. 内間恭武、前田清、西口幸雄、西原承浩、八代正和、中村志郎、松本誉之、平川弘聖.41.大腸癌を合併した潰瘍性大腸炎症例の検討.癌の臨床 48(12);769-774,.2002.
  104. 前田清、八代正和、西原承浩、石川哲郎、西口幸雄、平川弘聖.42.腹腔鏡併用小開腹法による容易な大腸亜全摘術の試み.手術 56(11);1781-1784,.2002.
  105. 前田清、八代正和、平川弘聖.43.特集:悪性腫瘍治療中のサポーティブセラピー~大腸癌治療におけるサポーティブセラピーの実態~.成人病と生活習慣病 32(9);1155-1157,.2002.
  106. 平川弘聖,小野田尚佳,八代正和.35.胃癌発生の背景因子小川道雄編 初版.消化器外科へるす出版25-39,.2001.
  107. 曽和融生,加藤保之,八代正和,平川弘聖.36.スキルス胃癌?基礎と臨床からー.日本臨床59: 257-266,.2001.
  108. 沢井正光,西口幸雄,八代正和,雪本清隆,山下好人,平川弘聖. ヒト腫瘍細胞の増殖に及ぼすケトン体の効果に関する実験的研究.外科と代謝35: 317-322,.2001.
  109. 平川弘聖,八代正和. 胃癌の腹膜播種性転移能に影響する因子.外科62: 272-277,.2000.
  110. 西口幸雄,前田清,八代正和,繁沢晃,井上透,平川弘聖.30.潰瘍性大腸炎緊急例の治療戦略.日本腹部救急医学会雑誌20: 29-34,.2000.
  111. 前田清,西口幸雄,八代正和,平川弘聖.31.切除不能左側大腸悪性狭窄に対するexpandable metalic stent留置術の検討.日本臨床外科学会雑誌,61:3171-3176,.2000.
  112. 八代正和、大平雅一、平川弘聖. スキルス胃癌の特異性について. 綜合臨牀 49(9): 2377-2381, 2000.
  113. 澤田鉄二,寺岡均,西原承浩,須浪毅,八代正和,山下好人,山田靖哉,前田清,仲田文造,平川弘聖.32.膵癌肝転移能に関与する分子生物学的因子の解析.日本消化器外科学会雑誌33: 549-553,.2000.
  114. 井上透,八代正和,西村重彦,松岡翼,山下好人,山田靖哉,澤田鉄二,仲田文造,大平雅一,平川弘聖.33.胃癌の腹膜播種性転移能に影響する因子の分子生物学的検討.日本消化器外科学会雑誌33: 523-528,.2000.
  115. 小野田尚佳,前田清,澤田鉄二,八代正和,大平雅一,石川哲郎,平川弘聖.34.残遺の癌のサーベイランス法.消化器外科:23,1101-1106,.2000.
  116. 寺岡均、澤田鉄二、山本篤、西原承浩、小山剛、山下好人、八代正和、関守一、西野裕二、平川弘聖.25.膵癌肝転移におけるTGF-β1の及ぼす影響~とくにVEGFへの関与について~.医学のあゆみ191; 1079-1080,.1999.
  117. 寺岡均、澤田鉄二、山本篤、西原承浩、山下好人、八代正和、平川弘聖.26.膵癌細胞におけるTGF-β1の抗腫瘍免疫能に及ぼす影響.Biotherapy 14: 45-47. 1999.
  118. 大平雅一,堀武治,清水貞利,山下好人,山田靖哉,八代正和,澤田鉄二,西野裕二,吉川和彦,平川弘聖.27.食道静脈瘤圧からみたEVL治療後の静脈瘤再発に関する検討.日本門脈圧亢進症学会雑誌5:267-271,.1999.
  119. 前田清、西口幸雄、小野田尚佳、仲田文造、八代正和、大谷博、池原照幸、奥野匡宥、平川弘聖、曽和融生.24.大腸癌家族歴の有無とhMSH2遺伝子蛋白発現との関係.医学のあゆみ187: 977-978,.1998.
  120. 松岡翼,鄭容錫,八代正和,西村重彦,井上透,冨士原知史,澤田鉄二,前田清,仲田文造,曽和融生. 接着ペプチドによる腹膜播種性胃癌細胞の接着・浸潤抑制.日本消化器外科学会雑誌 30,799,1997.
  121. 富士原知史、鄭容錫、八代正和、井上 透、松岡 翼、澤田鉄二、前田清,仲田文造、加藤保之,曽和融生. 胃癌におけるICAM-1の発現と臨床病理学的検討.Biotherapy 11(5):615.1997.
  122. 鄭容錫,西村重彦, 八代正和、井上 透、曽和融生.23.腹膜播種性転移における癌細胞と間質の相互作用.Biotherapy 11:987-992.1997.
  123. 曽和融生, 八代正和, 西村重彦, 鄭容錫:.14.腹膜転移の機序とその治療の可能性,.癌と化学療法 23,.1996.
  124. 西村重彦,鄭容錫,八代正和,井上 透、松岡 翼、前田清,小野田尚佳,澤田鉄二、仲田文造、曽和融生.15.4型スキルス胃癌の腹膜播種における接着分子CD44Hの関与.医学のあゆみ179: 525-526,.1996.
  125. 曽和融生, 加藤保之,西村重彦、八代正和、鄭容錫.16.膜播種性転移胃癌(その特性からみた治療への考慮),.外科治療 75(3): 698-702.1996.
  126. 八代正和、鄭容錫、西村重彦、井上 透、松岡 翼、富士原知史、澤田鉄二、仲田文造、曽和融生.17.胃癌腹膜播種性転移機序に関与する因子.消化器科,23(6): 597-604.1996.
  127. 池田光慶,西口幸雄,鄭容錫,有本祐一,山田靖哉,八代正和,曽和融生.18.癌悪液質に及ぼすサイトカインの関与ー実験的検討ー.Biotherapy, 10: 213-216,.1996.
  128. 八代正和、鄭容錫、西村重彦、井上 透、曽和融生.7.腹膜播種性転移における腹膜線維化の意義・.消化器癌の発生と進展・7:281-282.1995.
  129. 西村重彦、鄭容錫、八代正和、井上 透、曽和融生.8.腹膜播種成立過程における4型スキルス胃癌細胞の腹膜中皮細胞への影響・.消化器癌の発生と進展・7:449-451.1995.
  130. 山田靖哉、鄭容錫、有本裕一、高塚聡,西村重彦、八代正和、澤田鉄二、奥野匡宥、曽和融生.癌培養細胞株の高転移能獲得における核DNA量の変化について.癌と化学療法・22巻・172-175.1995.
  131. 鄭容錫、八代正和、西村重彦、井上 透、松岡 翼、前田清、澤田鉄二、仲田文造、加藤保之、曽和融生.10.胃癌腹膜播種の病態と新しい治療の可能性.消化器外科・18: 1899-1908.1995.
  132. 仲田文造、小野田尚佳、鄭容錫、前田清、西村重彦、新田敦範、加藤保之、八代正和、久保俊彰、曽和融生.11.胃癌におけるc- myc遺伝子の発現と悪性度.癌と化学療法・22巻・176-179.1995.
  133. 澤田鉄二、鄭容錫、有本裕一、前田清、八代正和、西村重彦、井上 透,曽和融生.12.膵癌肝転移における糖鎖抗原発現とELAM-1接着および糖鎖合成阻害剤の治療応用への可能性,.消化器癌の発生と進展・7:49-51.1995.
  134. 八代正和、鄭容錫、西村重彦,山田靖哉、澤田鉄二、久保俊彰、仲田文造、曽和融生. スキルス胃癌原発巣由来細胞株OCUM-2Mの樹立と増殖因子の関与:.日本消化器病学会雑誌92,199-205. 1995.
  135. 八代正和、鄭容錫、久保俊彰、西村重彦、山田靖哉、澤田鉄二、加藤保之、曽和融生.3.スキルス胃癌由来の高播種性転移モデルの作成.日本外科学会雑誌・95巻・288.1994.
  136. 新田敦範、鄭容錫、加藤保之、八代正和、前田清、久保俊彰、仲田文造、奥野匡宥、曽和融生.4.各種Cisplatin 誘導体に対する胃癌細胞株の感受性の検討.癌と化学療法・21巻・5号・701-703.1994.
  137. 澤田鉄二、鄭容錫、曽我部豊志,山田靖哉、有本裕一、八代正和、山下好人,高塚聡,奥野匡宥、曽和融生.5.ヒト膵癌細胞の浸潤,転移能における遊走因子の関与.日本消化器外科学会雑誌・27巻・2413-2418.1994.
  138. 西村重彦、鄭容錫、八代正和、山田靖哉、澤田鉄二、澤田隆吾,久保俊彰、仲田文造、加藤保之、曽和融生.6.スキルス胃癌由来の腹膜播種における着床機転に関する検討.消化器癌の発生と進展・6:405-408.1994.
  139. 八代正和、鄭容錫、久保俊彰、前田清、山田靖哉、小野田尚佳、有本裕一、新田敦範、澤田隆吾、加藤保之、奥野匡宥、曽和融生.1.スキルス胃癌細胞株に及ぼす胃壁由来線維芽細胞の影響.日本消化器外科学会雑誌・26巻・2554.1993.
  140. 八代正和、鄭容錫、久保俊彰、前田清、山田靖哉、小野田尚佳、有本裕一、新田敦範、澤田隆吾、加藤保之、奥野匡宥、曽和融生.2.胃壁由来線維芽細胞のスキルス胃癌細胞株に及ぼすの影響.消化器癌の発生と進展・vol 5・371-373.1993.


PAGE TOP